MA46778B1 - Composition intranasale comprenant de la bétahistine - Google Patents

Composition intranasale comprenant de la bétahistine

Info

Publication number
MA46778B1
MA46778B1 MA46778A MA46778A MA46778B1 MA 46778 B1 MA46778 B1 MA 46778B1 MA 46778 A MA46778 A MA 46778A MA 46778 A MA46778 A MA 46778A MA 46778 B1 MA46778 B1 MA 46778B1
Authority
MA
Morocco
Prior art keywords
betahistine
intranasal composition
intranasal
otological
composition
Prior art date
Application number
MA46778A
Other languages
English (en)
Other versions
MA46778A1 (fr
Inventor
Christopher John Wraight
Thomas Meyer
Original Assignee
Otolanum Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otolanum Ag filed Critical Otolanum Ag
Publication of MA46778A1 publication Critical patent/MA46778A1/fr
Publication of MA46778B1 publication Critical patent/MA46778B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant en tant que substance active de la bétahistine ou un sel pharmaceutiquement acceptable de celle-ci, destinée à être utilisée dans le traitement de troubles otologiques ou neurologiques chez un sujet humain par application intranasale.
MA46778A 2017-02-02 2018-02-02 Composition intranasale comprenant de la bétahistine MA46778B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762453931P 2017-02-02 2017-02-02
PCT/EP2018/052695 WO2018141922A1 (fr) 2017-02-02 2018-02-02 Composition intranasale comprenant de la bétahistine

Publications (2)

Publication Number Publication Date
MA46778A1 MA46778A1 (fr) 2021-04-30
MA46778B1 true MA46778B1 (fr) 2022-08-31

Family

ID=61187302

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46778A MA46778B1 (fr) 2017-02-02 2018-02-02 Composition intranasale comprenant de la bétahistine

Country Status (33)

Country Link
US (2) US10456386B2 (fr)
EP (2) EP3474850B1 (fr)
JP (3) JP7714323B2 (fr)
KR (1) KR102653545B1 (fr)
CN (2) CN118356397A (fr)
AR (1) AR111699A1 (fr)
AU (1) AU2018216970B2 (fr)
CA (1) CA3051725A1 (fr)
CL (1) CL2019002145A1 (fr)
CO (1) CO2019008657A2 (fr)
DK (2) DK3698791T3 (fr)
EA (1) EA201991817A1 (fr)
ES (2) ES2969301T3 (fr)
FI (1) FI3698791T3 (fr)
HR (2) HRP20201137T1 (fr)
HU (2) HUE065336T2 (fr)
IL (1) IL268353B2 (fr)
LT (2) LT3698791T (fr)
MA (1) MA46778B1 (fr)
MX (1) MX381932B (fr)
MY (1) MY196333A (fr)
NZ (1) NZ755931A (fr)
PH (1) PH12019501785B1 (fr)
PL (2) PL3474850T3 (fr)
PT (2) PT3474850T (fr)
RS (2) RS60554B1 (fr)
SA (1) SA519402324B1 (fr)
SG (1) SG11201906980YA (fr)
SI (2) SI3474850T1 (fr)
TN (1) TN2019000220A1 (fr)
TW (1) TWI760429B (fr)
WO (1) WO2018141922A1 (fr)
ZA (1) ZA201904955B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170532A1 (fr) * 2017-03-22 2018-09-27 Franz, Lilian Ann Procéde de traitement
CA3179806A1 (fr) * 2020-04-14 2021-10-21 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Formulation pour pulverisation nasale ayant des bienfaits hydratants
JP2023523410A (ja) * 2020-04-22 2023-06-05 サノタイズ リサーチ アンド ディベロップメント コープ． 上気道感染症を治療するための組成物および方法
WO2026062705A1 (fr) 2024-09-23 2026-03-26 Troikaa Pharmaceuticals Limited Compositions liquides oromucosales de bétahistine ou de son ou de ses sels pharmaceutiquement acceptables et leurs procédés de préparation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397840B1 (fr) 1977-07-22 1981-03-20 Cherqui Jean
IT1229237B (it) * 1989-05-08 1991-07-26 Prodotti Formenti Sali di (2-(piridil)etil) metilammina
JPH03287535A (ja) * 1990-03-31 1991-12-18 Bairon Boeki Kk プラノプロフェン水溶液
JP3203056B2 (ja) * 1992-08-13 2001-08-27 株式会社ティ・ティ・エス技術研究所 メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JPH10139667A (ja) * 1996-11-15 1998-05-26 Yoshitomi Pharmaceut Ind Ltd 水性液剤
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
JP3555598B2 (ja) 2001-06-27 2004-08-18 株式会社村田製作所 積層型インダクタ
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
JP4733333B2 (ja) * 2002-12-26 2011-07-27 ライオン株式会社 点鼻剤又は洗鼻剤
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
AU2006202950A1 (en) * 2004-04-22 2006-10-19 Mor Research Applications Ltd. Methods and Compositions for Weight Management
JP2007533733A (ja) 2004-04-22 2007-11-22 モル リサーチ アプリケーションズ リミテッド 食物摂取管理の方法
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2006025882A2 (fr) 2004-08-25 2006-03-09 The Uab Research Foundation Substances ameliorant l'absorption destinees a l'administration de medicaments
WO2007022345A2 (fr) * 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Compositions de pulverisation nasale de vitamine b12 et leurs methodes d'utilisation
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
WO2007076140A2 (fr) * 2005-12-23 2007-07-05 University Of Cincinnati Procedes de traitement employant des antagonistes d’histamine h3 y compris de la betahistine
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
BRPI0821647A2 (pt) * 2007-12-21 2015-06-16 Schering Plough Healthcare Realce da fotosestabillização de oximetazolina
EP2278999B1 (fr) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Préparations auriculaires de traitement de maladies et états otiques
CN102046170B (zh) * 2008-05-27 2012-11-28 墨尔本大学 治疗患有咽鼓管功能障碍的哺乳动物的方法
ES2589915T3 (es) * 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
US10471040B2 (en) * 2014-10-03 2019-11-12 Lachesis Biosciences Limited Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Also Published As

Publication number Publication date
JP2022051872A (ja) 2022-04-01
LT3474850T (lt) 2020-08-10
ZA201904955B (en) 2021-05-26
NZ755931A (en) 2022-07-29
US10456386B2 (en) 2019-10-29
TWI760429B (zh) 2022-04-11
CN110418643A (zh) 2019-11-05
AU2018216970B2 (en) 2023-12-21
EP3474850A1 (fr) 2019-05-01
JP2024019731A (ja) 2024-02-09
PH12019501785B1 (en) 2024-02-28
AR111699A1 (es) 2019-08-14
IL268353B2 (en) 2023-10-01
US20180214432A1 (en) 2018-08-02
PL3474850T3 (pl) 2020-09-21
TN2019000220A1 (en) 2021-01-07
MX2019008961A (es) 2019-10-15
FI3698791T3 (fi) 2024-01-11
CN118356397A (zh) 2024-07-19
DK3698791T3 (da) 2024-01-15
RS65099B1 (sr) 2024-02-29
EP3474850B1 (fr) 2020-04-22
HUE050829T2 (hu) 2021-01-28
JP2020506930A (ja) 2020-03-05
CO2019008657A2 (es) 2020-01-17
PL3698791T3 (pl) 2024-04-08
EP3698791A1 (fr) 2020-08-26
DK3474850T3 (da) 2020-08-03
HRP20201137T1 (hr) 2021-01-22
SI3474850T1 (sl) 2020-09-30
MY196333A (en) 2023-03-24
KR20190116341A (ko) 2019-10-14
JP7714323B2 (ja) 2025-07-29
IL268353B1 (en) 2023-06-01
PH12019501785A1 (en) 2020-07-06
RS60554B1 (sr) 2020-08-31
EA201991817A1 (ru) 2020-01-27
CA3051725A1 (fr) 2018-08-09
IL268353A (en) 2019-09-26
HRP20231706T1 (hr) 2024-03-15
ES2807798T3 (es) 2021-02-24
TW201831179A (zh) 2018-09-01
AU2018216970A1 (en) 2019-08-22
MA46778A1 (fr) 2021-04-30
ES2969301T3 (es) 2024-05-17
PT3474850T (pt) 2020-07-27
PT3698791T (pt) 2024-01-12
US20200022963A1 (en) 2020-01-23
SG11201906980YA (en) 2019-08-27
LT3698791T (lt) 2024-02-12
CL2019002145A1 (es) 2019-11-04
BR112019015687A2 (pt) 2020-04-28
WO2018141922A1 (fr) 2018-08-09
SI3698791T1 (sl) 2024-05-31
KR102653545B1 (ko) 2024-04-04
MX381932B (es) 2025-03-13
HUE065336T2 (hu) 2024-05-28
EP3698791B1 (fr) 2023-10-25
SA519402324B1 (ar) 2023-03-16

Similar Documents

Publication Publication Date Title
MA43828B1 (fr) Agents thérapeutiques pour maladies neurodégénératives
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA39359A1 (fr) Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés
BR112015019412A2 (pt) inibidores de bace1
EP3643723A4 (fr) Nouveau peptide et composition pharmaceutique pour le traitement de maladies oculaires comprenant ledit nouveau peptide en tant que principe actif
MA46778B1 (fr) Composition intranasale comprenant de la bétahistine
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
MA50406B1 (fr) Inhibiteurs pyrazole de magl
EP3842423A4 (fr) Dérivé de 3-azabicyclo[3,1,1]heptane et composition pharmaceutique le comprenant
MX384072B (es) Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa.
EP3539550A4 (fr) Composition pharmaceutique pour la prevention ou le traitement de maladies neurodegeneratives comprenant comme principe actif de l'extrait de fleur de daphné lilas ou des fractions de celui-ci
EP3791869A4 (fr) Composition pharmaceutique de prévention ou de traitement de maladies neurodégénératives comprenant l'agent d'acétylation cox2 comme ingrédient actif
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta
BR112020026014A8 (pt) Derivado de lactama condensado
EP3698801A4 (fr) Composition pharmaceutique pour prévenir et traiter le diabète contenant un sel de zinc, un cyclo-hispro et un antidiabétique à titre de principes actifs
MA50383B1 (fr) Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
CO2017007691A2 (es) Inhibidores de la β-secretasa derivados de la 5-amino-3-(5-(3-isoxazol-5-il)-3-(fluorometil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina o 5-amino-3-(5-(1h-1,2,3-triazol-4-il)-2-fluorofenil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina composiciones que los comprenden y métodos de elaboración
EP3991727A4 (fr) Composition pour le traitement de maladies dégénératives du cerveau, contenant du 2-pentylfurane en tant que principe actif
EP3741366A4 (fr) Composition pharmaceutique comprenant une dunnione à titre de principe actif pour la prévention ou le traitement de la perte de cheveux
EA202190317A1 (ru) Лекарственный препарат для наружного применения